T1D-DN kpmp urban rural (T1D-DN KUR) recruitment site
Active Cooperative Agreement Awarded Last action
- Award ID
- U01DK144994
- Recipient
-
Mayo Clinic UEI Y2K4F9RPRRG7 Part of Mayo Clinic
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,581,130
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date 24% complete
- Place of performance
- Rochester, MN 55905, USA
Award details come from USAspending.gov.
Description
- Abstract
- This application, submitted by a multi-disciplinary research team, responds to RFA-DK-25-022: precision medicine for type 1 diabetic nephropathy (U01 clinical trial not allowed). The goal of the RFA is to expand the kidney precision medicine project (kpmp) by adding new research sites to recruit individuals with type 1 diabetes (T1D) at various stages of or high risk for diabetic nephropathy (DN) for a longitudinal study involving research kidney biopsies at enrollment. Our institution is well-positioned to enroll a diverse T1D population, supported by robust electronic databases for participant recruitment and phenotype determination. We have extensive experience with clinical trials in the T1D population, enhancing our ability to recruit and retain participants. Resources include a T1D registry and the expanded rochester epidemiology project (e-REP), covering 27 counties in minnesota and wisconsin, linking medical records for over 60 years. This includes populations from rural regions with lower socioeconomic status, often underrepresented in clinical research we have integrated the housing-based socioeconomic status (houses) index and rural-urban commuting area (ruca) classifications into a technology-enabled subject recruitment system (tesrs) to enhance recruitment efficiency from rural and under-resourced populations. In addition, we have access to institutional cohorts performing genetic testing with archived samples and laboratory measurements including renal function. Support from ethicists experienced in biorepository consent and genomic research result return, along with patient advocacy partnerships, will help implement kpmp protocols for kidney tissue biopsy procurement. The development of surrogate markers for early and progressive kidney injury, including novel image-based biomarkers and cardiovascular (CV) events proposed by US aims to clarify disease pathways and identify high- risk T1D patients for DN and CV morbidity and mortality. Results of this project may facilitate drug discovery and has potential to improve outcomes of people with T1D DN.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $790,565 | |
| Amendment | $0 | |
| Original award | $790,565 |
Quick answers
Who received award U01DK144994?
U01DK144994 was awarded to Mayo Clinic by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 1, 2025.
How much is award U01DK144994 worth?
$1,581,130 has been obligated on U01DK144994.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award